Tag - MRUS

Markets

SVB Leerink starts Merus at OP; PT $33

SVB Leerink launched coverage of Merus NV (NASDAQ:MRUS) with an “outperform” rating and $33 price target. The stock closed at $22.04 on March 15. Merus is focused on developing novel bispecific and trispecific...

March 16, 2021

Markets

HCW starts Merus NV at buy; PT $23

H.C. Wainwright launched coverage of Merus NV (NASDAQ:MRUS) with a “buy” rating and $23 price target. The stock closed at $15.80 on June 25. “Given the recent advances in structure-based design, bispecific antibodies...

June 26, 2020

Developments

Merus treats first patient with MCLA-145 in Phase 1 trial for solid tumors

Merus (NASDAQ:MRUS) treated the first patient with MCLA-145, a bispecific antibody therapeutic candidate, in its Phase 1 trial for the treatment of solid tumors. MCLA-145 is an immunostimulatory molecule that binds to...

May 10, 2019

Tag - MRUS

SVB Leerink starts Merus at OP; PT $33

HCW starts Merus NV at buy; PT $23

Merus treats first patient with MCLA-145 in Phase 1 trial for solid tumors

General

More